Hematologic Oncology

Amitkumar Mehta, MD, discusses complexities and considerations around sequencing CAR T-cell therapies and bispecific antibodies in lymphoma.

Areej El-Jawahri, MD, discusses a trial investigating a multimodal intervention to enhance sexual function in patients who have previously received HSCT.

Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.

Geoffrey Shouse, DO, PhD, discusses the importance of performing next-generation sequencing in patients with follicular lymphoma.

A panel of experts discusses the use of CALBG 10403 in patients with AYA ALL, highlighting adverse events reported with the regimen and mitigation practices.

Michael Grunwald, MD, presents the case of a 32-year-old woman with AYA ALL, and Kelly Weaver, NP, DNP, discusses the role of cytogenetics in diagnosing patients with AYA ALL.

Idoroenyi Amanam, MD, discusses adverse effects associated with JAK inhibitors in myelofibrosis.

Andrew Hantel, MD, discusses the evaluation of eligibility criteria in acute myeloid leukemia clinical trials that may perpetuate racial disparities.

Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

The FDA has approved axatilimab for adult and pediatric patients with cGVHD who have progressed on at least 2 prior lines of systemic therapy.

Experts on acute lymphoblastic leukemia discuss administration practices for asparaginase erwinia chrysanthemi and the importance of timely referrals and coordination of care.

Kelly Weaver, NP, DNP, and Grace Elsey, PharmD, outline adverse effects associated with asparaginase erwinia chrysanthemi in patients with ALL and actions that can be taken to mitigate them.

Enrollment will discontinue for the SELECT-AML-1 trial of tamibarotene/venetoclax/azacitidine in newly diagnosed, RARA-positive acute myeloid leukemia.

Areej El-Jawahri, MD, discusses a trial investigating a palliative oncology care model for patients with AML and MDS receiving nonintensive therapy.

Michael R. Grunwald, MD, discusses findings from a real-world study of risk factors related to disease progression in polycythemia vera.

Grace Elsey, PharmD, discusses the trial that led to the approval of asparaginase erwinia chrysanthemi and how it impacts AYA ALL treatment paradigms.

Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.

Francisco Hernandez-Ilizaliturri, MD, discusses deciding between CAR T-cell therapies or approved bispecific antibodies for diffuse large B-cell lymphoma.

Subcutaneous epcoritamab demonstrated safety when given in the outpatient setting in relapsed/refractory diffuse large B-cell and follicular lymphoma.

The FDA is requiring an additional trial demonstrating an OS benefit with Iomab-B to support the planned filing of the biologics license application for the agent.

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

Talha Munir, MBChB, PhD, discusses an adverse effect–based economic analysis of zanubrutinib vs acalabrutinib in patients with B-cell malignancies.